The future of depression research;Die zukunft der depressionsforschung

Nervenarzt

Volumn 81, Issue 11, 2010, Pages 1306-1316

  Holsboer, F ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Antidepressive agents; Biomarkers; Depression; Genetics; Pharmacotherapy

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER;

DEPRESSION; DISEASE MARKER; EARLY DIAGNOSIS; GENETIC SCREENING; HUMAN; MEDICAL RESEARCH; NEUROSCIENCE; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SYMPTOM;

ANTIDEPRESSIVE AGENTS; BIOMEDICAL RESEARCH; DEPRESSION; FORECASTING; GENE THERAPY; GENETIC TESTING; HUMANS;

EID: 78650208474     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-010-3053-1     Document Type: Review

References (31)

1. Angst J (1961) A clinical analysis of the effects of tofranil in depression. Longitudinal and follow-up studies. Treatment of blood-relations. Psychopharmacologia 2:381-407
2. Angst J, Sellaro R, Stassen HH, Gamma A (2005) Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J Affect Disord 84:149-157
3. Bardeleben U, Holsboer F (1989) Cortisol response to a combined dexamethasone-human corticotrophin-releasing hormone challenge in patients with depression. J Neuroendocrinol 1:485-488
4. Barden N, Harvey M, Gagne B et al (2006) Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet 141 B: 374-382
5. Binder E, Salyakina D, Lichtner P et al (2004) Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36:1319-132
6. Binneman B, Feltner D, Kolluri S et al (2008) A 6-week randomized, placebo-controlled trial of CP-316, 311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165:617-620
7. Craddock N, O'Donovan MC, Owen MJ (2006) Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull 32:9-16
8. Craddock N, Owen MJ (2010) The Kraepelinian dichotomy-going, going ⋯ but still not gone. Br J Psychiatry 196:92-95
9. Kloet ER de, Joels M, Holsboer F (2005) Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6:463-475
10. Green EK, Grozeva D, Raybould R et al (2009) P2RX7: a bipolar and unipolar disorder candidate susceptibility gene? Am J Med Genet B Neuropsychiatr Genet 150 B: 1063-1069
11. Green EK, Grozeva D, Jones I et al (2009) The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry (Epub ahead of print)
12. Heim C, Nemeroff CB (2001) The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry 49:1023-1039
13. Heuser I, Yassouridis A, Holsboer F (1994) The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28:341-356
14. Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501
15. Holsboer F, Bardeleben U von, Steiger A (1988) Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man. Neuroendocrinology 48:32-38
16. Holsboer F (1999) The rationale for corticotropinreleasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 33:181-214
17. Holsboer F (2008) How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 9:638-646
18. Holsboer F, Ising M (2010) Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 61:81-109
19. Kimura M, Müller-Preuss P, Lu A et al (2010) Conditional CRH overexpression in the mouse brain enhances REM sleep. Mol Psychiatry 15 (2):154-165
20. Lu A, Steiner MA, Whittle N et al (2008) Conditional CRH overexpressing mice: an animal model for stress-elicited pathologies and treatments that target the central CRH system. Mol Psychiatry 13:989
21. Lucae S, Salyakina D, Barden N et al (2006) P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet 15:2438-2445
22. McMahon FJ, Akula N, Schulze TG et al (2010) Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet 42:128-131
23. Metzker ML (2010) Sequencing technology. Nat Rev Genet 11:31-46
24. Murgatroyd C, Patchev AV, Wu Y et al (2009) Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci 12:1559-1566
25. Santarelli L, Saxe M, Gross C et al (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809
26. Snyder JS, Choe JS, Clifford MA et al (2009) Adultborn hippocampal neurons are more numerous, faster maturing, and more involved in behavior in rats than in mice. J Neurosci 29:14484-14495
27. Uher R (2008) The implications of gene-environment interactions in depression: will cause inform cure? Mol Psychiatry 13:1070-1078
28. Uhr M, Tontsch A, Namendorf C et al (2008) Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57:203-209
29. Williams HJ, Norton N, Dwyer S et al (2010) Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry (Epub ahead of print)
30. Yehuda R, Flory J, Pratchett L et al (2010) Putative Biological Mechanisms for the Association between Early Life Adversity and the Subsequent Development of PTSD. Psychopharmacology (Epub ahead of print)
31. Zobel AW, Nickel T, Kunzel HE et al (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181